The Canadian Forces Health Services Group is seeking an expert researcher to conduct a prospective cohort study of Canadian Armed Forces (CAF) personnel and Veterans experiencing PTSD to identify neural activation patterns and biomolecular signatures associated with the processing of traumatic memories, which may stem in part from situations they experienced during deployment(s) that conflicted with their beliefs about what is and is not morally/ethically appropriate (moral injury).

The Canadian Institute for Military and Veteran Health Research (CIMVHR) has entered into partnership with the Government of Canada to procure Research and Development Services related to the mental, social and physical wellbeing of active military members, Veterans and their families. CIMVHR is seeking Notices of Interest from qualified researchers or a research team to enter into a contract with CIMVHR to produce this Work.

The FY16 Defense Appropriations Act provides $30 million (M) to the Department of Defense Spinal Cord InjuryResearch Program (SCIRP) to support innovative, high-impact spinal cord injury research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, Research, Development, and Acquisition (DHA RDA) Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

FY16 SCIRP Program Announcements and General Application Instructions for the following award mechanism is posted on the Grants.gov website. 

http://cdmrp.army.mil/funding/scirp.shtml

Clinical Research Development Award – Letter of Intent due September 7, 2016

Independent investigators at all academic levels (or equivalent)

·    Preproposal is required; application submission is by invitation only.

·    Fund research that will establish the necessary collaborations and develop the necessary research resources that will serve as a foundation for investigator-initiated clinical research.

·    Clinical trials not allowed.

·      Maximum funding of $100,000 for direct costs (plus indirect costs)

·      Maximum period of performance is 1 year

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

Applications must be submitted through the federal government’s single-entry portal, Grants.gov.   For email notification when Program Announcements are released go to the CDMRP website (http://cdmrp.army.mil) and select Subscribe to Funding Opportunities & Program Communications.  For more information about the SCIRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org

Biomedical Research Grants provide financial support to medical researchers to assist in defraying the operating costs of research, which may include the purchase of materials, supplies and equipment and the payment of laboratory assistants.

Grants are available for one, two or three years, commencing July 1, for up to $50,000 per year. The research must be carried out in Canada.

2017 Competition - Important Dates 

Innovation Grants have been created to support innovative, creative problem solving in cancer research. As competition for grant funding increases, peer review panels become more conservative and risk averse, emphasizing feasibility more than innovation. The goal of this CCSRI grant program is to support unconventional concepts, approaches or methodologies to address problems in cancer research. Innovation projects will include elements of creativity, curiosity, investigation, exploration and opportunity. Successful projects may be based on “high risk” ideas, but will have the potential for “high reward” (i.e. to significantly impact our understanding of cancer and generate new approaches to combat the disease by introducing novel ideas into use or practice).

It is hoped that this grant program will accelerate the introduction of innovation into the entire cancer research system and contribute to the scientific idea pipeline. Significant findings from investigators funded by Innovation Grants may be developed further through CCSRI "Innovation to Impact" Grants or operating grants offered by other agencies.

The Genomic Applications Partnership Program (GAPP) represents a key element in Genome Canada’s strategic plan towards funding downstream research and development (R&D) projects that are driven by challenges and opportunities facing users of genomics based technologies. For the purpose of this program, “Users” include the various stakeholders that have an interest in “pulling” technologies and other results of genomics research from academia to market and application, including industry, government, not-for-profits, and other organizations.

The GAPP aims to:

• Promote the application of genomics-derived solutions to address key sector challenges or opportunities facing Users – User “pull”;
• Promote commercialization of genomics technologies by enabling the transfer of genomics-derived solutions from Academia to Users as well as de-risking and incentivizing follow-on investment from public and private partners;
• Increase the socio-economic impact of genomics research by accelerating its translation to application or market; and,
• Create and foster a more productive interface between Academia and Users.

Competition Timelines

Round 7:

The Mitacs Globalink Research Internship (GRI) is now accepting faculty submissions for Summer 2017. GRI pairs faculty in Canada with international undergrads for 12-week research projects from May to September.

• All disciplines are eligible
• Top-ranked senior undergrads travel from Australia, Brazil, China, France, Germany, India, Mexico, Tunisia, and Saudi Arabia
• Faculty can submit multiple projects and re-submit projects from previous years

Submit projects by June 16, 2016, at 5 p.m. PDT.

Questions? Visit our website or contact globalink@mitacs.ca. 

The FY16 Defense Appropriations Act provides $7.5 million (M) to the Department of Defense Autism Research Program (ARP) to support innovative, high-impact autism spectrum disorder research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, Research, Development, and Acquisition (DHA RDA) Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

FY16 ARP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

http://cdmrp.army.mil/funding/bcrp.shtml

Clinical Trial Award – Preapplication due 6/22/16

Investigators at or above the level of Associate Professor (or equivalent)

• Supports research with the potential to have a major impact on the treatment and/or management of autism spectrum disorder (ASD).
• Preliminary data relevant to the proposed project are required.
• Pre-application is required; application submission is by invitation only.

• Behavioral, cognitive, and other non-pharmacological therapies
• Pharmacological treatments in autism or well-defined subgroups of autism
• Dissemination/Implementation of efficacious behavioral interventions (including measures of fidelity and outcomes)
• Therapies to alleviate conditions co-occurring with ASD (e.g., sleep disturbances, gastrointestinal issues, aggression, depression, anxiety, attention deficit)

• Maximum funding for the entire period of performance is $1,000,000 in direct costs (plus indirect costs)
• Maximum period of performance is 4 years

Idea Development Award – Preapplication is due 6/22/16

Investigators at all academic levels (or equivalent)

• Supports the development of innovative, high-impact ideas that advance the understanding of ASD and ultimately lead to improved outcomes.
• Preliminary data are required.
• Multiple Principal Investigator (PI) Option: Up to three investigators may collaborate on a single application, each of whom will be recognized as a PI and receive a separate award.
• Pre-application is required; application submission is by invitation only.

• Assessment of novel therapeutics using valid preclinical models
• Environmental risk factors
• Mechanisms of heterogeneous clinical expression of ASD
• Mechanisms underlying conditions co-occurring with ASD (e.g., sleep disturbances, gastrointestinal issues, aggression, depression, anxiety, attention deficit)
• Factors promoting success in key transitions to independence for individuals living with ASD

• Maximum funding for the entire period of performance is $377,000 in direct costs (plus indirect costs)
• For multiple PIs, the combined funding for all PIs for the entire period of performance may not exceed $377,000 in direct costs (plus indirect costs)
• Maximum period of performance is 3 years

The FY16 Defense Appropriations Act provides $50 million (M) to the Department of Defense Peer Reviewed Cancer Research Program (PRCRP) to support innovative, high-impact cancer research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, Research, Development, and Acquisition (DHA RDA) Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/ Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

FY16 PRCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website. 

Congressionally Directed Topic Areas:  To be considered for funding, applications for the FY16 PRCRP must address at least one of the Topic Areas as directed by Congress.  Research applications in the areas of breast, prostate, lung (excluding mesothelioma), or ovarian cancer will not be accepted. 

The FY16 PRCRP Topic Areas are listed below:

*As derived from the National Cancer Institute Dictionary of Cancer terms¹: Immunotherapy is a type of biological therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer.  Cancers studied under this topic area should be within the scope of the Congressional language and the intent of the Program Announcement(s).

The FY16 PRCRP Military Relevance Focus Areas are listed below:

To address the cancer health needs of both deployed and non-deployed personnel, their dependents, retirees, and Veterans, the FY16 PRCRP seeks to support studies that are responsive to the Military Relevance Focus Areas listed below:

• Militarily relevant risk factors associated with cancer (e.g., ionizing radiation, chemicals, infectious agents, and environmental carcinogens)
• Gaps in cancer prevention, screening, early detection, diagnosis, treatment, and/or survivorship that may affect the general population but have a particularly profound impact on the health and well-being of military members, Veterans, and their beneficiaries

Applications that address exposures, conditions, or circumstances that are unique to the military, or disproportionately represented in a military beneficiary population, are the highest priority, though any applications that address the above focus areas will be considered.

http://cdmrp.army.mil/funding/prcrp.shtml

Career Development Award- Preproposal due 6/8/16

Principal Investigator (PI): Independent early-career investigator within 10 years after completion of his/her terminal degree (excluding time spent in residency or on family medical leave) by the time of the application submission deadline.

Designated Mentor: Investigators at or above the level of Associate Professor (or equivalent); must have a proven publication and funding record in cancer research. 

·         Preproposal is required; application submission is by invitation only.

·         Supports independent, early-career investigators to conduct impactful research with the mentorship of an experienced cancer researcher

·         Must address at least one of the FY16 PRCRP Topic Areas

·         Strongly encouraged to address at least one of the FY16 PRCRP Military Relevance Focus Areas

·         Preliminary data not required

Clinical trials are not allowed

·       Maximum funding for the entire period of performance is $360,000 for direct costs (plus indirect costs)

·       Maximum period of performance is 3 years

Idea Award with Special Focus – Preproposal due 6/8/16

Independent investigator with a faculty-level appointment (or equivalent).

·         Preproposal is required; application submission is by invitation only.

·         Supports innovative, untested, high-risk/potentially high-reward concepts, theories, paradigms, and/or methods in cancer research that are relevant to Service members, their families, and other military beneficiaries

·         Emphasis on innovation and military relevance/impact

·         Must address at least one of the FY16 PRCRP Topic Areas

·         Must address at least one of the FY16 PRCRP Military Relevance Focus Areas

·         Preliminary data not required

Clinical trials are not allowed

·       Maximum funding for the entire period of performance is $400,000 for direct costs (plus indirect costs)

·       Maximum period of performance is 2 years

Translational Team Science Award – Preproposal due 6/8/16

At least two and up to three PIs must partner in one overarching correlative or translational research study.

At least one of the PIs is encouraged to be a military or Department of Veterans Affairs investigator.

·         Preproposal is required; application submission is by invitation only.

·         Supports translational correlative studies associated with an ongoing or completed clinical trial and/or translational study that can lead to a future clinical trial or clinical application in cancer research that is relevant to Service members, their families, and other military beneficiaries

·         Not intended to support high throughput screenings, sequencing, etc.

·         Must address at least one of the FY16 PRCRP Topic Areas

·         Must address at least one of the FY16 PRCRP Military Relevance Focus Areas

·         Preliminary data is required

Clinical trials are not allowed

·       Maximum funding for the entire period of performance is $1,000,000 for direct costs (plus indirect costs)

·       Maximum period of performance is 3 years

A pre-application is required and must be submitted through the CDMRP electronic Biomedical Research Application Portal (eBRAP) website (https://eBRAP.org) prior to the pre-application deadline.  All applications must conform to the final Program Announcement(s) and General Application Instructions available for electronic downloading from the Grants.gov website.  Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all USAMRMC funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

Requests for email notification of the Program Announcement(s) release may be sent to help@eBRAP.org.  Email notifications of funding opportunities are sent as a courtesy and should not be used as a sole source of notification; applicants should monitor Grants.gov for official postings of funding opportunities.

For more information about the PRCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk

301-682-5507

help@eBrap.org

Applications to the Fiscal Year 2016 (FY16) Multiple Sclerosis Research Program (MSRP) are being solicited for the Defense Health Agency, Research, Development, and Acquisition (DHA RDA) Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA). As directed by the Office of the Assistant Secretary of Defense for Health Affairs (OASD[HA]), the DHA RDA Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for this Program Announcement/Funding Opportunity is the Congressionally Directed Medical Research Programs (CDMRP). The MSRP, established in FY09, is dedicated to supporting pioneering concepts and high-impact research that are relevant to the prevention, etiology, pathogenesis, assessment, and treatment of multiple sclerosis (MS) to ultimately lessen its personal and societal impact. Appropriations for the MSRP from FY09 through FY15 totaled $33.1 million (M). The FY16 appropriation is $6M.

Funding opportunities under this program:

• Pilot Clinical Trial Award
• Investigator Initiated Research Award
• Exploration - Hypothesis Development Award